Form 8-K BIOGEN INC. For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Biogen (BIIB) PT Raised to $292 at RBC Capital
August 2, 2024 6:24 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $282.00) while maintaining a Outperform rating.
The analyst comments "BIIB's 2Q was better than today's stock action might suggest; while the beat was in partially driven by a few... More
Biogen (BIIB) tops Q2 expectations, raises profit guidance
August 1, 2024 7:27 AM EDTBiogen (NASDAQ: BIIB) reported its second-quarter results on Thursday, surpassing analyst expectations with an adjusted EPS of $5.28, significantly higher than the estimated $4.01.
The company's revenue also exceeded forecasts, coming in at $2.47 billion against a consensus estimate of $2.39 billion. Despite a flat year-over-year (YoY) total revenue, the adjusted EPS saw a notable 31% increase YoY.
The pharmaceutical giant's strong performance is reflected in its raised full-year... More
